For how we live.
Smoking is the leading modifiable cause, and the most common presenting sign is blood in the urine. There is no recommended screening test, which makes that sign the thing to act on.
In KEYNOTE-B15/EV-304, perioperative enfortumab vedotin plus pembrolizumab lifted two-year event-free survival to 79.4% from 66.2% against standard cisplatin-based chemotherapy in patients fit for it.
The European Medicines Agency's March meeting produced five positive opinions, three of them for orphan-designated cancer and rare-disease treatments already available in some other markets.
In KEYNOTE-905/EV-303, adding enfortumab vedotin and pembrolizumab to surgery lifted two-year event-free survival to 74.7% from 39.4%. Serious side effects were common.